What 4 Analyst Ratings Have To Say About Legend Biotech
Portfolio Pulse from Benzinga Insights
Legend Biotech (NASDAQ:LEGN) has been evaluated by 4 analysts over the last three months, showing a mix of bullish to indifferent sentiments. The average 12-month price target is now $82.75, down 11.02% from the previous $93.00. Recent analyst actions include maintaining, raising, and announcing ratings with price targets ranging from $65.00 to $94.00. Legend Biotech, a clinical-stage biopharmaceutical company, has shown impressive revenue growth of 250.91% as of September 30, 2023, but struggles with profitability and efficiency metrics.
March 07, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Legend Biotech has received mixed analyst ratings with a downward revision in the average price target. The company's significant revenue growth contrasts with its profitability and efficiency challenges.
The mixed analyst ratings and the decrease in the average price target suggest uncertainty about Legend Biotech's future stock performance. However, the company's substantial revenue growth indicates strong business potential, which might counterbalance the negative aspects related to profitability and efficiency metrics in the short term. The overall impact on the stock price is likely to be neutral as positive revenue growth could offset concerns about profitability.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100